by Jeffrey Crawford, MD; Bruce E. Johnson, MD; and Gregory J. Riely, MD, PhD
Older patients with advanced non–small cell lung cancer (NSCLC) differ individually in their ability to tolerate combined chemotherapy and radiatio......READ MORE
by Jeffrey Crawford, MD; Bruce E. Johnson, MD; and Gregory J. Riely, MD, PhD
Dramatic advances have occurred in recent years in the treatment of non–small cell lung cancer (NSCLC). However, continued work is needed to achiev......READ MORE
by Jeffrey Crawford, MD; Bruce E. Johnson, MD; and Gregory J. Riely, MD, PhD
The treatment of non–small cell lung cancer (NSCLC) has advanced dramatically in recent years with the introduction of novel targeted agents and im......READ MORE
by Jeffrey Crawford, MD; Bruce E. Johnson, MD; and Gregory J. Riely, MD, PhD
The number of genetic abnormalities for which there are available targeted therapies continues to expand. This highlights the need for the broad mo......READ MORE
by Roy S. Herbst, MD, PhD; Bruce E. Johnson, MD; and Gregory J. Riely, MD, PhD
Next-generation sequencing early in the patient’s treatment course is important to broadly identify both common and rare oncogenic drivers of non–s......READ MORE
